Clinical Trial

Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an optimal pharmacokinetic/pharmacodynamic target. However, no study has yet evaluated this aspect in the specific scenario of liver transplant patients with documented infections with Gram-negative pathogens.
Trial Details
NCT Number NCT06718517
Lead Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions Liver Transplant Infection
Enrollment 65 participants
Start Date 2024-08-28
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-05